All In Biotech

Drug Trial Radar · NCT00814073

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis

Randomized, Placebo-controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib at 6 mg/kg/Day to Placebo in Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap

Last checked: Nov 20, 2026Latest source record: Dec 3, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 135 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

135

Actual

Start

Dec 2008

Primary completion

Nov 2015

Study completion Nov 2015

Sponsor

Lead sponsor
AB ScienceIndustry
Sponsor type
Industry
First posted
Dec 23, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to compare the safety and efficacy of masitinib (AB1010) to placebo in patients with mastocytosis with handicap.

Conditions

  • Indolent Systemic Mastocytosis

Interventions

  • MasitinibDrug

    Masitinib 6 mg/kg/day

  • PlaceboDrug

    Matching placebo

  • Best Supportive CareOther

    Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, proton pump inhibitors (PPI), sodium cromoglicate, antidepressants, leukotriene antagonists, interferon-alpha, 2-CdA, and corticosteroids.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative response (4R75%)Time frame: 24 weeks

Locations

24 sites in 2 countries. Site status is shown where the registry gives one.

  • UC Davis Health System , Department of Dermatology

    Sacramento, California

  • MD Anderson Cancer Centre

    Houston, Texas

  • CHU d'Amiens

    Amiens, France

  • Hôpital Avicenne

    Bobigny, France

  • CHU de Brest

    Brest, France

  • CHU de Caen

    Caen, France

  • CHU Clermont Ferrand

    Clermont-Ferrand, France

  • Hôpital Claude Huriez

    Lille, France

  • CHU Dupuytren

    Limoges, France

  • Hôpital Ambroise Paré

    Marseille, France

  • Hôpital Nord

    Marseille, France

  • Hôpital Central

    Nancy, France

  • CHU Hôtel Dieu

    Nantes, France

  • Hôpital l'Archet II

    Nice, France

  • Hôpital Necker

    Paris, France

  • Hôpital Tenon

    Paris, France

  • CHU Lyon Sud

    Pierre-Bénite, France

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, France

  • CHU Milétrie

    Poitiers, France

  • CHU Hôpital Sud

    Rennes, France

  • CHU de Saint-Etienne

    Saint-Etienne, France

  • Hôpital Purpan

    Toulouse, France

  • Hôpital Bretonneau

    Tours, France

  • Hôpital des Hauts Clos

    Troyes, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.